×
Hero Background

Geographic Atrophy GA Companies

ID: MRFR/HC/9297-HCR
120 Pages
Kinjoll Dey
October 2025

Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD), a progressive eye condition that can lead to vision loss. Geographic atrophy specifically involves the atrophy or degeneration of the central part of the retina known as the macula.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Geographic Atrophy (GA) Market Research Report—Global Forecast till 2035 Infographic
Summary Table of Contents Segmentation Download PDF

Top Industry Leaders in the Geographic Atrophy GA Market

Geographic Atrophy Key Companies

 


Latest Geographic Atrophy Companies Update:

Second FDA Approval for GA Treatment: In August 2023, Iveric Bio received FDA approval for Izervay (avacincaptad pegol), the second ever-approved treatment for GA after Syfovre (pegcetacoplan injection). This offers increased options and hope for patients.


Focus on Novel Treatment Approaches: Companies like Apellis Pharmaceuticals and Gyroscope Therapeutics are researching and developing gene therapy and stem cell-based therapies for GA, potentially offering long-term solutions.


Clinical Trial Momentum: Several promising Phase 3 clinical trials are underway for potential GA treatments, including NGM Bio's NGM621 and Alkeus Pharmaceuticals' Gildeuretinol.


Diagnostic Advancements: New imaging technologies like swept-source Optical Coherence Tomography (OCT) are improving early detection and monitoring of GA progression, leading to timely treatment initiation.


List of Geographic Atrophy Key companies in the market

  • Apellis Pharmaceuticals, Inc. (US)

  • Iveric Bio (US)

  • Alkeus Pharmaceuticals, Inc. (US)

  • Hemera Biosciences LLC (US)

  • Allegro Ophthalmics, LLC (US)

  • Stealth BioTherapeutics (Cayman Islands)

  • Gyroscope Therapeutics Limited (UK)

  • F. Hoffmann-La Roche AG (Switzerland)

  • Genentech, Inc. (US)

  • Gensight Biologics SA (France)